Mencari ubat atas namanya

Heparin and Dextrose dan Trombositopenia

Hasil ujian interaksi ubat Heparin and Dextrose dan penyakit Trombositopenia untuk kontraindikasi dan kesan sampingan dengan penggunaan bersama.

Hasil pemeriksaan:

Heparin and Dextrose <> Trombositopenia

Relevan: 23.07.2019 Pengulas: MD P.M. Shkutko, in

Kontraindikasi atau kesan sampingan yang boleh membahayakan atau meningkatkan kesan negatif apabila menggunakan ubat dengan penyakit ditemui saat pemeriksaan interaksi mengikut sumber yang bereputasi - Drugs.com, RXList.com, Webmd.com, MedScape.com.

Pengguna:

Penggunaan heparin disarankan pada pasien dengan thrombocytopenia teruk. Akut thrombocytopenia boleh berlaku pada pesakit menerima heparin, dengan melaporkan kejadian sehingga 30%. Platelet tuduhan harus mendapat sebelum dan secara berkala semasa heparin pentadbiran, termasuk biasa dan berulang-ulang penggunaan heparin flush penyelesaian jika diberikan untuk lebih dari 5 hari. Thrombocytopenia ringan dengan tuduhan atas 100,000/mm3 mungkin tetap stabil atau terbalik walaupun terus heparin pentadbiran. Bagaimanapun, thrombocytopenia mana-mana tahap perlu dipantau dengan teliti. Terapi harus dihentikan jika mengira jatuh di bawah 100,000/mm3 atau jika trombosis berulang membangun, dan alternatif, nonheparin antikoagulan (contohnya, argatroban, bivalirudin, lepirudin) diberikan jika perlu. Heparin-induced thrombocytopenia (PUKUL) serius antibodi-diselesaikan menyebabkan reaksi dari yang tidak dapat dipulihkan pengumpulan platelet. HIT boleh maju untuk pembangunan vena dan arteri thromboses, keadaan yang dirujuk sebagai heparin-induced thrombocytopenia dan trombosis (KETEPATAN). Trombotik peristiwa mungkin juga menjadi awal persembahan untuk KETEPATAN, dan mungkin termasuk dalam urat trombosis, paru-paru embolisme, cerebral urat trombosis, anggota iskemia, stroke, serangan jantung, mesenterik trombosis, arteri ginjal trombosis, kulit kebekuan, gangren kaki yang boleh membawa untuk pemotongan, dan mungkin kematian. Kedua-dua MEMUKUL dan KETEPATAN boleh berlaku sehingga beberapa minggu selepas pemberhentian heparin terapi. Pesakit menyampaikan dengan thrombocytopenia atau trombosis selepas pemberhentian heparin harus dinilai untuk MEMUKUL dan KETEPATAN. Berikut sebuah episode, bila-bila masa depan menggunakan heparin harus dihindari, dan menggunakan rendah berat molekul heparin harus mempertimbangkan potensi untuk reaktivitas-silang dengan HIT antibodi dan mendekati dengan sangat hati-hati, jika tidak disarankan.

Sumber

Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1007
Kelton JG, Sheridan D, Santos A, et al "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988): 925-30
Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993): 554-61
Berkowitz N, Beckman J "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1006
Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995): 37-44
Cines DB, Kaywin P, Bina M, et al "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980): 788-95
Rissieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996): 157
Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991): 1425-6
Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995): 736-8
Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986): 621-3
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996): 82-5
Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1007
"Product Information. Orgaran (danaparoid)." Organon, West Orange, NJ.
Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991): 1217
Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980): 902-7
Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992): 85-91
Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986): 11-8
Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994): 487-90
Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995): 20-5
Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996): 329-30
Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992): 192-3
Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989): 415-8
Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996): 404-5
Warkentin TE, Hayward CP, Smith CA, et al "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992): 371-9
Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990): 1077-8
Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996): 839-43
Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1006-7
Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996): 211-2
Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989): 415-8
"Product Information. Lovenox (enoxaparin)." Rhone-Poulenc Rorer, Collegeville, PA.
Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985): 760-4
Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995): 2528
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995): 1330-5
Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996): 157
Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993): 705-10
Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994): 61-3
Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992): 145-52
Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994): 1764-6
"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company, Indianapolis, IN.